WO2001005939A1 - Procede de production d'une substance cible par fermentation - Google Patents
Procede de production d'une substance cible par fermentation Download PDFInfo
- Publication number
- WO2001005939A1 WO2001005939A1 PCT/JP2000/004775 JP0004775W WO0105939A1 WO 2001005939 A1 WO2001005939 A1 WO 2001005939A1 JP 0004775 W JP0004775 W JP 0004775W WO 0105939 A1 WO0105939 A1 WO 0105939A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target substance
- gene
- microorganism
- strain
- katf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
Definitions
- the present invention relates to a method for producing a target substance using a microorganism, and more particularly, to a target substance such as L-amino acid, an antibiotic, a vitamin, a growth factor, or a physiologically active substance.
- the present invention discloses a method for improving the productivity of a target substance in a method for producing a target substance using microorganisms.
- BACKGROUND ART As a typical method for producing substances using microorganisms, a method for producing L-amino acid by fermentation is known. L-amino acids are used not only as seasonings and foods, but also as components of various nutritional mixtures for medical purposes.
- L-amino acids such as L-lysine and L-homoserine by microorganisms.
- Known microorganisms capable of producing L-amino acids by fermentation include coryneform bacteria, Escherichia bacteria, Bacillus bacteria, and Serratia bacteria.
- the productivity of target substances has been remarkably improved by the above-mentioned microorganism breeding technology.
- the present invention relates to a method for producing a target substance such as an L-amino acid, an antibiotic, a vitamin, a growth factor, or a physiologically active substance using a microorganism. It is an object of the present invention to provide a method for improving.
- the present inventors have conducted intensive studies to solve the above-mentioned problems. As a result, the productivity of the target substance is improved by using a mutant strain or a recombinant strain deficient in the ⁇ factor that functions specifically in the stationary phase. This led to the completion of the present invention.
- a method for producing a target substance using a microorganism wherein the microorganism is cultured in a medium, the target substance is produced and accumulated in the medium, and the target substance is collected.
- a method characterized in that the functionally functioning factor is a mutant strain or a recombinant strain in which the factor is weakened or deleted;
- the target substance produced by the present invention is not particularly limited as long as it is a substance that can be produced by a microorganism.
- L-threonine, L-lysine, L-glutamic acid, L-leucine, L-isoleucine, L-valine, L-feline Examples include various L-amino acids such as dilulanine.
- substances that are biosynthesized by microorganisms such as nucleic acids such as guanylic acid and inosinic acid, vitamins, antibiotics, growth factors, and bioactive substances.
- the present invention can be used for substances that are not currently produced using microorganisms, as long as they can be produced by microorganisms.
- the microorganism used in the present invention can be used without any particular limitation as long as it is a microorganism having an ability to produce a target substance, for example, a microorganism conventionally used for producing a useful substance by a fermentation method.
- the present invention can be applied to microorganisms that have not been conventionally used industrially as long as they have the ability to produce the target substance.
- the term “ability to produce a target substance” refers to the ability of a microorganism of the present invention to accumulate a significant amount of the target substance in the medium or in the cells when cultured in the medium.
- the microorganism of the present invention may originally have the ability to produce the target substance, or may have the ability to produce the target substance by breeding using a mutation method, recombinant DNA technology, or the like. You may.
- Escherichia bacteria such as Escherichia coli
- Coryneform bacteria such as Brevibacterium lactophamentum
- Bacillus bacteria such as Bacillus subtilis
- Serratia bacteria such as Serratia marcescens. But not limited to these.
- the target substance is L-threonine
- Escherichia coli VKPM B-3996 RIA 1867
- Corynepacterium acetoacidophilum AJ12318 FERM BP-1172
- L-lysine in the case of Escherichia coli AJ1144. 2 (NRRL B-12185, FERM 8? -1543)
- Brevibacterium lactofarmentum AJ3990 1 "( ⁇ 31269) see U.S. Pat. No.
- Lactofermen AJ3718 (FERM P-2516) (see U.S. Pat. No. 3,970,519) and the like.
- E. coli. 141 (VKPM B-4781) (see EP-A-519,113), Breviva Terium flavum AJ12149 (FERM BP-759) (see U.S. Pat. No. 4,656,135), and in the case of L-parin, Escherichia coli VL1970 (VKPM B-4411)) (European Patent Application Publication No. 519,113). ), And Brevipacterium lactofermentum AJ12341 (FERM BP-1763) (see U.S. Pat. No. 5,188,948).
- Escherichia coli AJ12604 (FERM BP-1763) is used.
- BP-3579 (see European Patent Application Publication No. 488,424)
- Brevibacterium lactofermentum AJ12637 (FERM BP-4160) (see French Patent Application Publication No. 2,686,898), and the like.
- the microorganism used in the present invention is a mutant or recombinant which has the ability to produce the target substance and lacks a factor which functions specifically in the stationary phase.
- holoenzyme are one of the sub-units of RNA polymerase. When holoenzyme is formed by binding to the RNA polymerase core enzyme, holoenzyme can recognize the gene promoter. it can.
- the phrase “a factor that functions specifically in the stationary phase is weakened” means that the factor binds to a core enzyme of RNA polymerase to form a holoenzyme or that a holoenzyme is formed. Even if possible, this includes cases where the function of the holoenzyme to recognize the promoter of the gene is weakened.
- the phrase “deficient in the ⁇ factor that functions specifically in the stationary phase” includes the case where the factor is not produced in the cell, or the case where the factor is produced but has no activity to recognize the promoter.
- RpoS factors that function specifically in the stationary phase
- katF gene also called rpoS gene
- RpoS gene factors that function specifically in the stationary phase
- rpoS gene also called rpoS gene.
- nucleotide sequence has been elucidated (Mulvey, R. et al., Nucleic Acids Res., 17 (23), 9979-9991 (1989), GenBank / EMBL / DDBJ Accession AF0828 44).
- the nucleotide sequence of the katF gene of the Escherichia coli K-12 strain and the amino acid sequence that it encodes are shown in SEQ ID NOs: 3 and 4 in the sequence listing.
- a strain deficient in RpoS can be obtained by disrupting the katF gene or causing a mutation in the katF gene so as not to express an active RpoS.
- the mutant strain used in the present invention can be obtained by subjecting a wild strain of a microorganism or a mutant strain having a preferable mutation for production of a target substance to a mutation treatment and selecting a mutant strain that does not produce active RpoS. Even a mutant strain that does not produce RpoS, but whose biosynthesis system of the target substance is not perfect, is not preferable as a microorganism used in the present invention.
- Mutation treatments include UV irradiation or treatment of microorganisms with a mutagen that is commonly used in mutation treatments such as N-methyl-1N, 12-trough N-nitrosoguanidine (NTG) or nitrite. No.
- the recombinant strain used in the present invention can be created by gene disruption by homologous recombination.
- Microorganisms can be transformed with DNA containing the katF gene, which has been modified so that it does not function properly by deleting the 5, 5 and / or 3, terminus of the gene (katF) encoding a factor that functions specifically in the stationary phase.
- the katF gene on the chromosome can be disrupted.
- Such gene disruption by homologous recombination has already been established, and gene disruption can also be performed by a method using linear DNA or a method using a plasmid containing a temperature-sensitive replication control region. A method using a plasmid containing a temperature-sensitive replication control region will be described below.
- Microorganisms are transformed with DNA containing a gene (deletion gene) that has been deleted so that it does not function properly by deleting the inside of the katF gene, and a pair is formed between the deletion gene and the excretory gene on the chromosome.
- a gene deletion gene
- the katF gene on the chromosome can be disrupted.
- the following procedure may be used to replace the deletion gene with the katF gene on the host chromosome. That is, a recombinant DNA is prepared by inserting a temperature-sensitive replication control region, a deletion gene, and a marker gene that is resistant to drugs such as Kuala ramphenicol, and a microorganism is transformed with the recombinant DNA.
- the strain in which the recombinant DNA has been integrated into the chromosome undergoes recombination with the katF gene sequence originally present on the chromosome, and two fusion genes of the katF gene and the deletion type gene on the chromosome become the recombinant DNA. It is inserted into the chromosome with other parts (vector part, temperature-sensitive replication control region and drug resistance marker) interposed therebetween. Therefore, in this state, the transformant produces active RpoS because the normal katF gene is dominant.
- one copy of the katF gene was recombined with the vector portion (including the temperature-sensitive replication control region and drug resistance marker) by recombination of the two katF genes.
- Remove from chromosomal DNA At that time, the normal katF gene is left on the chromosomal DNA and the deletion type gene is cut out, and conversely, the deletion type gene is left on the chromosome DNA and the normal katF gene is cut out. is there.
- the excised DNA is retained in the cell in the form of a plasmid when cultured at a temperature at which the temperature-sensitive replication control region functions.
- the target gene-disrupted strain can be selected by examining the chromosomal gene structure of the drug-sensitive strain at the non-permissive temperature by PCR.
- recA-1 could be introduced into the gene-disrupted strain to prevent the karF gene on plasmid from reintegrating into the chromosome during low-temperature culture. This is preferable because it can be prevented.
- the katF gene of Escherichia coli is, for example, a polymerase chain using the chromosomal DNA of Escherichia coli as a type III and an oligonucleotide having the nucleotide sequence shown in SEQ ID NOS: 1 and 2 as a primer. (PCR: polymerase chain reaction; White, T. J. et al., Trends Genet., 5, 18) 5 (1989)).
- plasmids those which function in bacteria belonging to the genus Escherichia such as Escherichia coli include, for example, pHSG415 and pHSG422 (Hashimoto-Gotoh, T. et al, Gene, 16, 227-235 ( 1981)), but those which function on coryneform bacteria such as Brevipacterium. Lactofu amenium include pHS4, pHS22 and PHS23.
- plasmid pHSC4 obtained by connecting a DNA fragment containing a replication control region derived from a coryneform bacterium excised from pHS4 to pHSG398, a vector for Escherichia coli, also has a similar temperature.
- pHSC4 grows autonomously in coryneform bacteria and Escherichia coli and confer chloramphenicol resistance to the host.
- Escherichia coli K. AJ 1257-1 which retains pH SC 4, was established on January 11, 1990 in the Institute of Biotechnology and Industrial Technology, Ministry of International Trade and Industry of the Ministry of International Trade and Industry (Zip code 305-85 66 Tsukuba, Ibaraki, Japan Deposit No. 1-3-1, Higashi-shi, Japan) and deposited under the accession number F ERM P-1 176 3; transferred to an international deposit under the Budapest Treaty on August 26, 1999; FERM BP—3 524 Has been deposited under the accession number.
- temperature-sensitive bubrasmid for Escherichia coli can autonomously grow in Escherichia coli cells at about 25 to 37 ° C, but cannot grow autonomously at about 42 ° C or higher.
- the temperature-sensitive plasmid for coryneform bacteria can grow autonomously in coryneform bacterial cells at about 10 to 32 ° C, but cannot grow autonomously at about 34 ° C or more.
- a DNA fragment having a temperature-sensitive replication control region can be obtained, for example, by excising the above pHSG415 with Ball or by excising pHSC4 with BamHI and Kpnl.
- the katF gene-disrupted microorganism obtained as described above lacks RpoS, so the growth period is longer than that of a strain in which katF functions normally, and as a result, the production of the target substance is improved. I do.
- the microorganism of the present invention is not only deficient in RpoS but also has other properties such as enhanced biosynthetic enzymes of the target substance. You may.
- the microorganism of the present invention may have a reduced or defective activity of an enzyme that catalyzes a reaction that produces a compound other than the target substance by branching off from the biosynthetic pathway of the target substance.
- the microorganism of the present invention may be provided with other properties that are favorable for production of the target substance.
- the target substance is produced by culturing a microorganism having an improved target substance production ability in a medium as described above, producing and accumulating the target substance in the medium, and collecting the target substance from the culture.
- the culture medium and culture conditions used for the culture may be appropriately selected depending on the host used.
- the target substance produced as described above can be used as necessary to purify the target substance from a cell extract or culture medium using standard methods such as ion-exchange chromatography, gel filtration chromatography, adsorption chromatography, and solvent precipitation. It can be purified using BEST MODE FOR CARRYING OUT THE INVENTION
- BEST MODE FOR CARRYING OUT THE INVENTION will be described more specifically with reference to examples.
- E. coli AJ13199 strain Total genomic DNA of the E. coli AJ13199 strain was prepared by the method of Saito and Miura (Biochem. Biophys. Acta., 72, 619 (1963)).
- Escherichia coli AJ13199 strain (see Japanese Patent Application Laid-Open No. 7-203980) is a DL-aspartic acid 5-hydroxamate-resistant strain, and on April 18, 1996, Institute of Biotechnology and Industrial Technology (Postal Code 305). -8566 Japan, Ibaraki Prefecture Tsukuba 1-3-1-3) Deposited under accession number FERM P-15573, 19 It was transferred to an international deposit under the Budapest Treaty on February 3, 1997, and given the accession number FERM BP-5807.
- This plasmid was used to transform Escherichia coli AJ13199 strain, an L-glutamic acid-producing bacterium of Escherichia coli, and the katF gene on the chromosome was replaced with a deletion type. Specifically, AJ13199 / p415ARP0S into which blasmid has been introduced is placed at 25 ° C in an LB medium (containing 10 g of park tributone, 5 g of pectin tract and 5 g of NaCl in 1 L of water) at 25 ° C.
- LB medium containing 10 g of park tributone, 5 g of pectin tract and 5 g of NaCl in 1 L of water
- the cells were spread on an LB agar medium containing 25 mg / ml of kanamycin, and cultured at 42 ° C to obtain a colony formed as a strain incorporating the plasmid.
- a strain which became susceptible to kanamycin at 42 ° C was obtained from this strain by the Levri force method. From the susceptible strain, the nucleotide sequence of the katF gene on the chromosome was examined, and it was confirmed that the gene was replaced with a deletion type. This was named ARpoS strain.
- the AJ13199 strain (transformant) and the AJ13199 / ARpoS strain were transformed into an L-glutamic acid production medium (composition: glucose 40.0 g / L, magnesium sulfate (separately sterilized) 1.0 g / L, ammonium sulfate 20.
- L-glutamic acid production medium composition: glucose 40.0 g / L, magnesium sulfate (separately sterilized) 1.0 g / L, ammonium sulfate 20.
- the growth period of a microorganism producing the target substance can be extended, and as a result, the productivity of the target substance can be improved.
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU60185/00A AU6018500A (en) | 1999-07-19 | 2000-07-14 | Process for producing target substance by fermentation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/205269 | 1999-07-19 | ||
JP20526999A JP2003204788A (ja) | 1999-07-19 | 1999-07-19 | 発酵法による目的物質の製造法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001005939A1 true WO2001005939A1 (fr) | 2001-01-25 |
Family
ID=16504190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004775 WO2001005939A1 (fr) | 1999-07-19 | 2000-07-14 | Procede de production d'une substance cible par fermentation |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003204788A (ja) |
AU (1) | AU6018500A (ja) |
WO (1) | WO2001005939A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004670A2 (en) | 2001-07-06 | 2003-01-16 | Degussa Ag | Process for the preparation of l-amino acids using strains of the enterobacteriaceae family with enhanced pts-g expression |
WO2003074719A3 (en) * | 2002-03-07 | 2004-03-04 | Degussa | Amino acid-producing bacteria and a process for preparing l-amino acids |
EP1715055A2 (de) | 2005-04-22 | 2006-10-25 | Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae |
EP1715056A1 (de) | 2005-04-23 | 2006-10-25 | Degussa AG | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae |
US7211415B2 (en) | 2003-04-09 | 2007-05-01 | Degussa Ag | Enterobacteriaceae strains over-expressing the yfiD gene for the fermentative production of L-amino acids |
US7256021B2 (en) | 2001-07-18 | 2007-08-14 | Degussa Ag | Enterobacteriaceae strains with an attenuated aspA gene for the fermentative production of amino acids |
WO2008020654A2 (en) * | 2006-08-18 | 2008-02-21 | Ajinomoto Co., Inc. | An l-glutamic acid producing bacterium and a method for producing l-glutamic acid |
JP2008067698A (ja) * | 2006-08-18 | 2008-03-27 | Ajinomoto Co Inc | L−グルタミン酸生産細菌及びl−グルタミン酸の製造法 |
DE102007051024A1 (de) | 2007-03-05 | 2008-09-11 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae |
EP1975241A1 (de) | 2007-03-29 | 2008-10-01 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2006386A1 (en) | 2002-03-13 | 2008-12-24 | Evonik Degussa GmbH | Process for the preparation of L-amino acids using strains of the Enterobacteriaceae family |
EP2036979A1 (de) | 2007-09-15 | 2009-03-18 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2055785A1 (de) | 2007-11-02 | 2009-05-06 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2060636A1 (de) | 2007-11-14 | 2009-05-20 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2083080A1 (en) | 2001-07-18 | 2009-07-29 | Evonik Degussa GmbH | Process for the preparation of l-amino acids using strains of the Enterobacteriaceae family which contain an enhanced rseA or rseC gene |
US7575905B2 (en) | 2004-02-06 | 2009-08-18 | Evonik Degussa Gmbh | Process for L-amino acid production using enterobacteriaceae strains with enhanced yibD |
EP2098597A1 (de) | 2008-03-04 | 2009-09-09 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
DE102008002309A1 (de) | 2008-06-09 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
US7638313B2 (en) | 2003-01-30 | 2009-12-29 | Degussa Ag | Processes for the fermentative preparation of L-threonine using strains of Escherichia in which the yjgF gene is inactivated |
DE102008044768A1 (de) | 2008-08-28 | 2010-03-04 | Evonik Degussa Gmbh | Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2267145A1 (de) | 2009-06-24 | 2010-12-29 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP3608409A1 (en) | 2018-08-09 | 2020-02-12 | Evonik Operations GmbH | Process for preparing l amino acids using improved strains of the enterobacteriaceae family |
-
1999
- 1999-07-19 JP JP20526999A patent/JP2003204788A/ja active Pending
-
2000
- 2000-07-14 AU AU60185/00A patent/AU6018500A/en not_active Abandoned
- 2000-07-14 WO PCT/JP2000/004775 patent/WO2001005939A1/ja active Application Filing
Non-Patent Citations (4)
Title |
---|
MCCANN M.P. ET AL.: "the putative sigma factor katF has a central role in development of starvation-mediated general resistance in Escherichia coli", JOURNAL OF BACTERIOLOGY,, vol. 173, no. 13, 1991, pages 4188 - 4194, XP002927741 * |
MULVEY M.R. ET AL.: "Cloning and physical characterization of katE and katF required for catalase HPII expression in Escherichia coli", GENE,, vol. 73, no. 2, 1988, pages 337 - 345, XP002927740 * |
MULVEY M.R. ET AL.: "Nucleotide sequence of katF of Escherichia coli suggests katF protein is a novel", NUCLEIC ACIDS RESEARCH,, vol. 17, no. 23, 1989, pages 9979 - 9991, XP002927739 * |
TOUATI E. ET AL.: "Are appR and katF the same Escherichia coli gene encoding a new sigma transcription initiation factor?", RES. MICROBIOL.,, vol. 142, no. 1, 1991, pages 29 - 36, XP002927742 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003004670A2 (en) | 2001-07-06 | 2003-01-16 | Degussa Ag | Process for the preparation of l-amino acids using strains of the enterobacteriaceae family with enhanced pts-g expression |
US7256021B2 (en) | 2001-07-18 | 2007-08-14 | Degussa Ag | Enterobacteriaceae strains with an attenuated aspA gene for the fermentative production of amino acids |
EP2083080A1 (en) | 2001-07-18 | 2009-07-29 | Evonik Degussa GmbH | Process for the preparation of l-amino acids using strains of the Enterobacteriaceae family which contain an enhanced rseA or rseC gene |
WO2003074719A3 (en) * | 2002-03-07 | 2004-03-04 | Degussa | Amino acid-producing bacteria and a process for preparing l-amino acids |
EP2006386A1 (en) | 2002-03-13 | 2008-12-24 | Evonik Degussa GmbH | Process for the preparation of L-amino acids using strains of the Enterobacteriaceae family |
US7638313B2 (en) | 2003-01-30 | 2009-12-29 | Degussa Ag | Processes for the fermentative preparation of L-threonine using strains of Escherichia in which the yjgF gene is inactivated |
US7211415B2 (en) | 2003-04-09 | 2007-05-01 | Degussa Ag | Enterobacteriaceae strains over-expressing the yfiD gene for the fermentative production of L-amino acids |
US7575905B2 (en) | 2004-02-06 | 2009-08-18 | Evonik Degussa Gmbh | Process for L-amino acid production using enterobacteriaceae strains with enhanced yibD |
EP1715055A2 (de) | 2005-04-22 | 2006-10-25 | Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae |
EP1715056A1 (de) | 2005-04-23 | 2006-10-25 | Degussa AG | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung verbesserter Stämme der Familie Enterobacteriaceae |
WO2008020654A3 (en) * | 2006-08-18 | 2008-05-02 | Ajinomoto Kk | An l-glutamic acid producing bacterium and a method for producing l-glutamic acid |
US8222007B2 (en) | 2006-08-18 | 2012-07-17 | Ajinomoto Co., Inc. | L-glutamic acid producing bacterium and a method for producing L-glutamic acid |
US20090215131A1 (en) * | 2006-08-18 | 2009-08-27 | Yoshihiko Hara | L-glutamic acid producing bacterium and a method for producing l-glutamic acid |
JP2008067698A (ja) * | 2006-08-18 | 2008-03-27 | Ajinomoto Co Inc | L−グルタミン酸生産細菌及びl−グルタミン酸の製造法 |
WO2008020654A2 (en) * | 2006-08-18 | 2008-02-21 | Ajinomoto Co., Inc. | An l-glutamic acid producing bacterium and a method for producing l-glutamic acid |
DE102007051024A1 (de) | 2007-03-05 | 2008-09-11 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von Stämmen der Familie Enterobacteriaceae |
EP1975241A1 (de) | 2007-03-29 | 2008-10-01 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2036979A1 (de) | 2007-09-15 | 2009-03-18 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
DE102007044134A1 (de) | 2007-09-15 | 2009-03-19 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2055785A1 (de) | 2007-11-02 | 2009-05-06 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2465869A1 (de) | 2007-11-02 | 2012-06-20 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
DE102007052270A1 (de) | 2007-11-02 | 2009-05-07 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2060636A1 (de) | 2007-11-14 | 2009-05-20 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2098597A1 (de) | 2008-03-04 | 2009-09-09 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
DE102008002309A1 (de) | 2008-06-09 | 2009-12-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2133420A1 (de) | 2008-06-09 | 2009-12-16 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
DE102008044768A1 (de) | 2008-08-28 | 2010-03-04 | Evonik Degussa Gmbh | Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2163613A2 (de) | 2008-08-28 | 2010-03-17 | Evonik Degussa GmbH | Verfahren zur Herstellung von organisch-chemischen Verbindungen unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP2267145A1 (de) | 2009-06-24 | 2010-12-29 | Evonik Degussa GmbH | Verfahren zur Herstellung von L-Aminosäuren unter Verwendung von verbesserten Stämmen der Familie Enterobacteriaceae |
EP3608409A1 (en) | 2018-08-09 | 2020-02-12 | Evonik Operations GmbH | Process for preparing l amino acids using improved strains of the enterobacteriaceae family |
Also Published As
Publication number | Publication date |
---|---|
AU6018500A (en) | 2001-02-05 |
JP2003204788A (ja) | 2003-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001005939A1 (fr) | Procede de production d'une substance cible par fermentation | |
EP1687408B1 (en) | Method for producing l-amino acid by fermentation | |
EP1149911B1 (en) | Amino acid producing strains belonging to the genus Escherichia and method for producing an amino acid | |
EP1526181B1 (en) | Method for producing l-amino acid using bacteria belonging to the genus escherichia | |
JP3106501B2 (ja) | L−リジンの製造法 | |
EP0931833B1 (en) | Method of producing L-serine by fermentation | |
KR100823044B1 (ko) | 트레오닌 및 이소류신의 제조방법 | |
KR101110580B1 (ko) | 표적 물질의 제조 방법 | |
US8486670B2 (en) | Method of producing L-threonine using Escherichia coli strain with phosphoenolpyruvate carboxylase promoter replaced with cysteine synthase promoter | |
US5929221A (en) | Gene derived from coryneform bacteria and use thereof | |
JP2002017363A (ja) | 微生物を利用した物質の製造法 | |
US5407824A (en) | Recombinant coryneform bacterium for producing L-tryptophan | |
JP2656300B2 (ja) | L−トリプトファンの製造法 | |
US7163810B2 (en) | Method for producing target substance | |
EP1689876B1 (en) | L-threonine producing bacterium belonging to the genus escherichia and method for producing l-threonine | |
WO2001005959A1 (fr) | Obtention d'une substance cible par un procede de fermentation | |
KR940011838B1 (ko) | 유전자 조작 미생물 발효에 의한 l-페닐알라닌의 제조방법 | |
JPH0847397A (ja) | 発酵法によるl−イソロイシンの製造法 | |
JP2023506053A (ja) | クエン酸シンターゼの活性が弱化した新規な変異型ポリペプチド及びそれを用いたl-アミノ酸生産方法 | |
JP2003503064A (ja) | 炭素同化の調節 | |
JP2005333855A (ja) | ピルビン酸の製造方法及びl−バリンの製造方法 | |
JP4742521B2 (ja) | 目的物質の製造法 | |
JP2003204783A (ja) | 発酵法による目的物質の製造法 | |
BamHI | S kkkk I |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |